<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">33477892</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>09</Month>
        <Day>24</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>09</Month>
        <Day>24</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1718-7729</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>28</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Jan</Month>
              <Day>19</Day>
            </PubDate>
          </JournalIssue>
          <Title>Current oncology (Toronto, Ont.)</Title>
          <ISOAbbreviation>Curr Oncol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>A Rare Coexistence of Paraneoplastic Cerebellar Degeneration: Papillary Thyroid Carcinoma.</ArticleTitle>
        <Pagination>
          <StartPage>560</StartPage>
          <EndPage>564</EndPage>
          <MedlinePgn>560-564</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.3390/curroncol28010055</ELocationID>
        <Abstract>
          <AbstractText>Paraneoplastic cerebellar degeneration (PCD) is a rare neuroimmunological disease that may accompany tumors. In this article, we present a patient with progressive gait difficulty who was diagnosed with PCD and, in a rare comorbidity, with papillary thyroid carcinoma (PTC) following malignancy screening. A 46-year-old male patient reported having experienced poor balance for 2 years. A neurological examination revealed nystagmus, intention tremor, and ataxia, and anti-thyroid peroxidase and anti-thyroglobulin levels were found to be elevated. A brain MRI showed significant cerebellar atrophy in the superior vermis. Malignancy screening for PCD was performed, and thyroid ultrasonography revealed a nodule in the left lobe, while PET/CT detected elevated focal F-18 fluorodeoxyglucose uptake in the thyroid. Onconeuronal antibodies (anti-Hu, anti-Yo, anti-Ri, anti-amphiphysin, anti-Tr, anti-PPCA-2, anti-Ma, anti-CV-1, and anti-ANNA-3) were negative. Pathologic examination of the thyroid revealed PTC, for which the patient was treated with 0.4 g/kg intravenous immunoglobulin and referred to the medical oncology department. This case demonstrates that clinicians must be alert to the rare comorbidity of PCD and PTC.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Ayas</LastName>
            <ForeName>Zeynep Özözen</ForeName>
            <Initials>ZÖ</Initials>
            <Identifier Source="ORCID">0000-0002-9302-5543</Identifier>
            <AffiliationInfo>
              <Affiliation>Eskisehir City Hospital, Department of Neurology, Eskisehir 26080, Turkey.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Uncu</LastName>
            <ForeName>Gülgün</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Eskisehir City Hospital, Department of Neurology, Eskisehir 26080, Turkey.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D002363">Case Reports</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>01</Month>
          <Day>19</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Curr Oncol</MedlineTA>
        <NlmUniqueID>9502503</NlmUniqueID>
        <ISSNLinking>1198-0052</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020362" MajorTopicYN="Y">Paraneoplastic Cerebellar Degeneration</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000072078" MajorTopicYN="N">Positron Emission Tomography Computed Tomography</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000077273" MajorTopicYN="N">Thyroid Cancer, Papillary</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013964" MajorTopicYN="Y">Thyroid Neoplasms</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">ataxia</Keyword>
        <Keyword MajorTopicYN="Y">papillary thyroid carcinoma</Keyword>
        <Keyword MajorTopicYN="Y">paraneoplastic cerebellar degeneration</Keyword>
      </KeywordList>
      <CoiStatement>No conflict of interest was declared by the authors</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>11</Month>
          <Day>18</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2020</Year>
          <Month>12</Month>
          <Day>16</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>12</Month>
          <Day>30</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>1</Month>
          <Day>22</Day>
          <Hour>1</Hour>
          <Minute>3</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>1</Month>
          <Day>23</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>25</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33477892</ArticleId>
        <ArticleId IdType="pmc">PMC7903265</ArticleId>
        <ArticleId IdType="doi">10.3390/curroncol28010055</ArticleId>
        <ArticleId IdType="pii">curroncol28010055</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Anderson N.E., Rosenblum M.K., Posner J.B. Paraneoplastic cerebellar degeneration: Clinical-immunological correlations. Ann. Neurol. 1988;24:559–567. doi: 10.1002/ana.410240413.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ana.410240413</ArticleId>
            <ArticleId IdType="pubmed">3239956</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Graus F., Delattre J.Y., Antoine J.C., Dalmau J., Giometto B., Grisold W., Honnorat J., Smitt P.S., Vedeler C.H., Verschuuren J.J., et al.  Recommended diagnostic criteria for paraneoplastic neurological syndromes. J. Neurol. Neurosurg. Psychiatry. 2004;75:1135–1140. doi: 10.1136/jnnp.2003.034447.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jnnp.2003.034447</ArticleId>
            <ArticleId IdType="pmc">PMC1739186</ArticleId>
            <ArticleId IdType="pubmed">15258215</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Papanicolaou Society of Cytopathology Recommendations for Thyroid Fine Needle Aspiration.  [(accessed on 27 July 2007)]; Available online:  www.papsociety.org/guidelines.html.</Citation>
        </Reference>
        <Reference>
          <Citation>Odell W.D.  Paraneoplastic Syndromes. In: Bast R.C. Jr., Kufe D.W., Pollock R.E., Weichselbaum R.R., Holland J.F., Frei E. III, editors. Holland-Frei Cancer Medicine. BC Decker; Hamilton, ON, Canada: 2003. </Citation>
        </Reference>
        <Reference>
          <Citation>Yshii L.M., Gebauer C.M., Pignolet B., Maure E., Queriault C., Pierau M., Saito H., Suzuki N., Brunner-Weinzierl M., Bauer J., et al.  CTLA4 blockade elicits paraneoplastic neurological disease in a mouse model. Brain. 2016;139:2923–2934. doi: 10.1093/brain/aww225.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/brain/aww225</ArticleId>
            <ArticleId IdType="pubmed">27604307</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Panja D., Vedeler C.A., Schubert M. Paraneoplastic cerebellar degeneration: Yo antibody alters mitochondrial calcium buffering capacity. Neuropathol. Appl. Neurobiol. 2019;45:141–156. doi: 10.1111/nan.12492.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/nan.12492</ArticleId>
            <ArticleId IdType="pmc">PMC7379599</ArticleId>
            <ArticleId IdType="pubmed">29679372</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kroiss A., Uprimny C., Virgolini I.J. Thyroid carcinoma detected by incidental (18)F-FDG uptake in a patient with progressive cerebellar syndrome. Endocrine. 2016;51:199–200. doi: 10.1007/s12020-015-0646-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12020-015-0646-2</ArticleId>
            <ArticleId IdType="pubmed">26077948</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gratwicke J.P., Alli A., Rollin M., Vaz F., Rees J., Vincent A., Edwards M. Paraneoplastic cerbellar syndrome and sensory ganglionopathy with papillary thyroid carcinoma. J. Neurol. Sci. 2014;15341:183–184. doi: 10.1016/j.jns.2014.03.042.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jns.2014.03.042</ArticleId>
            <ArticleId IdType="pubmed">24735737</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vogrig A., Bernardini A., Gigli G.L., Corazza E., Marini A., Segatti S., Fabris M., Honnorat J., Valente M. Stroke-like presentation of paraneoplastic cerebellar degeneration: A single-center experience and review of the literature. Cerebellum. 2019;18:976–982. doi: 10.1007/s12311-019-01075-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12311-019-01075-9</ArticleId>
            <ArticleId IdType="pubmed">31463826</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hezer S., Descargues G., Vignals C., Imbert Y. Paraneoplastic cerebellar degeneration and primary fallopian cancer. Gynecol. Obstet. Fertil. Senol. 2019;47:610–612.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31239210</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Le May M., Dent S. Anti-Yo antibody-mediated paraneoplastic cerebellar degeneration associated with cognitive affective syndrome in a patient with breast cancer: A case report and literature review. Curr. Oncol. 2018;25:e585–e591. doi: 10.3747/co.25.4106.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3747/co.25.4106</ArticleId>
            <ArticleId IdType="pmc">PMC6291278</ArticleId>
            <ArticleId IdType="pubmed">30607127</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shams’ili S., Grefkens J., de Leeuw B., van den Bent M., Hooijkaas H., van der Holt B., Vecht C., Sillevis Smitt P. Paraneoplastic cerebellar degeneration associated with antineuronal antibodies: Analysis of 50 patients. Brain. 2003;126:1409–1418. doi: 10.1093/brain/awg133.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/brain/awg133</ArticleId>
            <ArticleId IdType="pubmed">12764061</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Waterhouse D.M., Natale R.B., Cody R.L. Breast cancer and paraneoplastic cerebellar degeneration. Cancer. 1991;68:1835–1841.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1913530</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hens M.J., Camacho B., Maestre A., Gonzalez V., Villegas I., Magana M. Renal cell carcinoma presenting as paraneoplastic neurological dysfuntion. Actas Urol. Esp. 2008;32:645–648. doi: 10.1016/S0210-4806(08)73902-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0210-4806(08)73902-0</ArticleId>
            <ArticleId IdType="pubmed">18655350</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Darnell R.B. Onconeural antigens and the paraneoplastic neurologic disorders: At the intersection of cancer, immunity, and the brain. Proc. Natl. Acad. Sci. USA. 1996;93:4529–4545. doi: 10.1073/pnas.93.10.4529.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.93.10.4529</ArticleId>
            <ArticleId IdType="pmc">PMC39311</ArticleId>
            <ArticleId IdType="pubmed">8643438</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rojas I., Graus F., Keime-Guibert F., Rene R., Delattre J.Y., Ramon J.M., Dalmau J., Posner J.B. Long-term clinical outcome of paraneoplastic cerebellar degeneration and anti-Yo antibodies. Neurology. 2000;55:713–715. doi: 10.1212/WNL.55.5.713.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.55.5.713</ArticleId>
            <ArticleId IdType="pubmed">10980743</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">33477892</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>09</Month>
        <Day>24</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>09</Month>
        <Day>24</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1718-7729</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>28</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Jan</Month>
              <Day>19</Day>
            </PubDate>
          </JournalIssue>
          <Title>Current oncology (Toronto, Ont.)</Title>
          <ISOAbbreviation>Curr Oncol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>A Rare Coexistence of Paraneoplastic Cerebellar Degeneration: Papillary Thyroid Carcinoma.</ArticleTitle>
        <Pagination>
          <StartPage>560</StartPage>
          <EndPage>564</EndPage>
          <MedlinePgn>560-564</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.3390/curroncol28010055</ELocationID>
        <Abstract>
          <AbstractText>Paraneoplastic cerebellar degeneration (PCD) is a rare neuroimmunological disease that may accompany tumors. In this article, we present a patient with progressive gait difficulty who was diagnosed with PCD and, in a rare comorbidity, with papillary thyroid carcinoma (PTC) following malignancy screening. A 46-year-old male patient reported having experienced poor balance for 2 years. A neurological examination revealed nystagmus, intention tremor, and ataxia, and anti-thyroid peroxidase and anti-thyroglobulin levels were found to be elevated. A brain MRI showed significant cerebellar atrophy in the superior vermis. Malignancy screening for PCD was performed, and thyroid ultrasonography revealed a nodule in the left lobe, while PET/CT detected elevated focal F-18 fluorodeoxyglucose uptake in the thyroid. Onconeuronal antibodies (anti-Hu, anti-Yo, anti-Ri, anti-amphiphysin, anti-Tr, anti-PPCA-2, anti-Ma, anti-CV-1, and anti-ANNA-3) were negative. Pathologic examination of the thyroid revealed PTC, for which the patient was treated with 0.4 g/kg intravenous immunoglobulin and referred to the medical oncology department. This case demonstrates that clinicians must be alert to the rare comorbidity of PCD and PTC.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Ayas</LastName>
            <ForeName>Zeynep Özözen</ForeName>
            <Initials>ZÖ</Initials>
            <Identifier Source="ORCID">0000-0002-9302-5543</Identifier>
            <AffiliationInfo>
              <Affiliation>Eskisehir City Hospital, Department of Neurology, Eskisehir 26080, Turkey.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Uncu</LastName>
            <ForeName>Gülgün</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Eskisehir City Hospital, Department of Neurology, Eskisehir 26080, Turkey.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D002363">Case Reports</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>01</Month>
          <Day>19</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Curr Oncol</MedlineTA>
        <NlmUniqueID>9502503</NlmUniqueID>
        <ISSNLinking>1198-0052</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020362" MajorTopicYN="Y">Paraneoplastic Cerebellar Degeneration</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000072078" MajorTopicYN="N">Positron Emission Tomography Computed Tomography</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000077273" MajorTopicYN="N">Thyroid Cancer, Papillary</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013964" MajorTopicYN="Y">Thyroid Neoplasms</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">ataxia</Keyword>
        <Keyword MajorTopicYN="Y">papillary thyroid carcinoma</Keyword>
        <Keyword MajorTopicYN="Y">paraneoplastic cerebellar degeneration</Keyword>
      </KeywordList>
      <CoiStatement>No conflict of interest was declared by the authors</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>11</Month>
          <Day>18</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2020</Year>
          <Month>12</Month>
          <Day>16</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>12</Month>
          <Day>30</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>1</Month>
          <Day>22</Day>
          <Hour>1</Hour>
          <Minute>3</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>1</Month>
          <Day>23</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>25</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33477892</ArticleId>
        <ArticleId IdType="pmc">PMC7903265</ArticleId>
        <ArticleId IdType="doi">10.3390/curroncol28010055</ArticleId>
        <ArticleId IdType="pii">curroncol28010055</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Anderson N.E., Rosenblum M.K., Posner J.B. Paraneoplastic cerebellar degeneration: Clinical-immunological correlations. Ann. Neurol. 1988;24:559–567. doi: 10.1002/ana.410240413.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ana.410240413</ArticleId>
            <ArticleId IdType="pubmed">3239956</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Graus F., Delattre J.Y., Antoine J.C., Dalmau J., Giometto B., Grisold W., Honnorat J., Smitt P.S., Vedeler C.H., Verschuuren J.J., et al.  Recommended diagnostic criteria for paraneoplastic neurological syndromes. J. Neurol. Neurosurg. Psychiatry. 2004;75:1135–1140. doi: 10.1136/jnnp.2003.034447.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jnnp.2003.034447</ArticleId>
            <ArticleId IdType="pmc">PMC1739186</ArticleId>
            <ArticleId IdType="pubmed">15258215</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Papanicolaou Society of Cytopathology Recommendations for Thyroid Fine Needle Aspiration.  [(accessed on 27 July 2007)]; Available online:  www.papsociety.org/guidelines.html.</Citation>
        </Reference>
        <Reference>
          <Citation>Odell W.D.  Paraneoplastic Syndromes. In: Bast R.C. Jr., Kufe D.W., Pollock R.E., Weichselbaum R.R., Holland J.F., Frei E. III, editors. Holland-Frei Cancer Medicine. BC Decker; Hamilton, ON, Canada: 2003. </Citation>
        </Reference>
        <Reference>
          <Citation>Yshii L.M., Gebauer C.M., Pignolet B., Maure E., Queriault C., Pierau M., Saito H., Suzuki N., Brunner-Weinzierl M., Bauer J., et al.  CTLA4 blockade elicits paraneoplastic neurological disease in a mouse model. Brain. 2016;139:2923–2934. doi: 10.1093/brain/aww225.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/brain/aww225</ArticleId>
            <ArticleId IdType="pubmed">27604307</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Panja D., Vedeler C.A., Schubert M. Paraneoplastic cerebellar degeneration: Yo antibody alters mitochondrial calcium buffering capacity. Neuropathol. Appl. Neurobiol. 2019;45:141–156. doi: 10.1111/nan.12492.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/nan.12492</ArticleId>
            <ArticleId IdType="pmc">PMC7379599</ArticleId>
            <ArticleId IdType="pubmed">29679372</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kroiss A., Uprimny C., Virgolini I.J. Thyroid carcinoma detected by incidental (18)F-FDG uptake in a patient with progressive cerebellar syndrome. Endocrine. 2016;51:199–200. doi: 10.1007/s12020-015-0646-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12020-015-0646-2</ArticleId>
            <ArticleId IdType="pubmed">26077948</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gratwicke J.P., Alli A., Rollin M., Vaz F., Rees J., Vincent A., Edwards M. Paraneoplastic cerbellar syndrome and sensory ganglionopathy with papillary thyroid carcinoma. J. Neurol. Sci. 2014;15341:183–184. doi: 10.1016/j.jns.2014.03.042.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jns.2014.03.042</ArticleId>
            <ArticleId IdType="pubmed">24735737</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vogrig A., Bernardini A., Gigli G.L., Corazza E., Marini A., Segatti S., Fabris M., Honnorat J., Valente M. Stroke-like presentation of paraneoplastic cerebellar degeneration: A single-center experience and review of the literature. Cerebellum. 2019;18:976–982. doi: 10.1007/s12311-019-01075-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12311-019-01075-9</ArticleId>
            <ArticleId IdType="pubmed">31463826</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hezer S., Descargues G., Vignals C., Imbert Y. Paraneoplastic cerebellar degeneration and primary fallopian cancer. Gynecol. Obstet. Fertil. Senol. 2019;47:610–612.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31239210</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Le May M., Dent S. Anti-Yo antibody-mediated paraneoplastic cerebellar degeneration associated with cognitive affective syndrome in a patient with breast cancer: A case report and literature review. Curr. Oncol. 2018;25:e585–e591. doi: 10.3747/co.25.4106.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3747/co.25.4106</ArticleId>
            <ArticleId IdType="pmc">PMC6291278</ArticleId>
            <ArticleId IdType="pubmed">30607127</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shams’ili S., Grefkens J., de Leeuw B., van den Bent M., Hooijkaas H., van der Holt B., Vecht C., Sillevis Smitt P. Paraneoplastic cerebellar degeneration associated with antineuronal antibodies: Analysis of 50 patients. Brain. 2003;126:1409–1418. doi: 10.1093/brain/awg133.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/brain/awg133</ArticleId>
            <ArticleId IdType="pubmed">12764061</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Waterhouse D.M., Natale R.B., Cody R.L. Breast cancer and paraneoplastic cerebellar degeneration. Cancer. 1991;68:1835–1841.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1913530</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hens M.J., Camacho B., Maestre A., Gonzalez V., Villegas I., Magana M. Renal cell carcinoma presenting as paraneoplastic neurological dysfuntion. Actas Urol. Esp. 2008;32:645–648. doi: 10.1016/S0210-4806(08)73902-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0210-4806(08)73902-0</ArticleId>
            <ArticleId IdType="pubmed">18655350</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Darnell R.B. Onconeural antigens and the paraneoplastic neurologic disorders: At the intersection of cancer, immunity, and the brain. Proc. Natl. Acad. Sci. USA. 1996;93:4529–4545. doi: 10.1073/pnas.93.10.4529.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.93.10.4529</ArticleId>
            <ArticleId IdType="pmc">PMC39311</ArticleId>
            <ArticleId IdType="pubmed">8643438</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rojas I., Graus F., Keime-Guibert F., Rene R., Delattre J.Y., Ramon J.M., Dalmau J., Posner J.B. Long-term clinical outcome of paraneoplastic cerebellar degeneration and anti-Yo antibodies. Neurology. 2000;55:713–715. doi: 10.1212/WNL.55.5.713.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.55.5.713</ArticleId>
            <ArticleId IdType="pubmed">10980743</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
